Eldecalcitol (ED-71), CAS NO.:104121-92-8, NMR, HPLC 99.45%, LCMS, COA, Pls kindly check:
Name: Eldecalcitol
CAS NO.: 104121-92-8
Chemical Formula: C30H50O5
Exact Mass: 490.3658
Molecular Weight: 490.725
Elemental Analysis: C, 73.43; H, 10.27; O, 16.30
Eldecalcitol (ED-71) Intermediates:
1. ED-71 intermediates 1, CAS No.:70550-73-1, NMR, HPLC 98%, LCMS, COA, 10G in stock.
CHEMICAL STRUCTURE:
2. ED-71 intermediates 2, CAS No.:144901-90-6, NMR, HPLC 98%, LCMS, COA, 10g in stock.
CHEMICAL STRUCTURE:
3. ED-71 intermediates 3, CAS No.:239100-35-7, NMR, HPLC 98%, LCMS, COA, 8g in stock.
CHEMICAL STRUCTURE:
4. ED-71 intermediates 4, CAS No.:64190-52-9, NMR, HPLC 98%, LCMS, COA, 10g in stock.
CHEMICAL STRUCTURE:
@IE@Q~3LTBY(}Q[H)@0.png)
5. ED-71 intermediates 5, CAS No.:79918-70-0, NMR, HPLC 98%, LCMS, COA, 5g in stock.
REFERENCES
1: Takada J, Ikeda S, Kusanagi T, Mizuno S, Wada H, Iba K, Yoshizaki T, Yamashita T. Comparison of the effects of eldecalcitol with either raloxifene or bisphosphonate on serum tartrate resistant acid phosphatase-5b, a bone resorption marker, in postmenopausal osteoporosis. Clin Cases Miner Bone Metab. 2016 Jan-Apr;13(1):25-8. doi: 10.11138/ccmbm/2016.13.1.025. Epub 2016 May 11. PubMed PMID: 27252739; PubMed Central PMCID: PMC4869948.
2: Erratum: Treatment of osteoporosis with eldecalcitol, a new vitamin D analog: a comprehensive review and meta-analysis of randomized clinical trials [Corrigendum]. Drug Des Devel Ther. 2016 Feb 15;10:697. doi: 10.2147/DDDT.S105820. eCollection 2016. PubMed PMID: 26929600; PubMed Central PMCID: PMC4760662.
3: Xu Z, Fan C, Zhao X, Tao H. Treatment of osteoporosis with eldecalcitol, a new vitamin D analog: a comprehensive review and meta-analysis of randomized clinical trials. Drug Des Devel Ther. 2016 Jan 28;10:509-17. doi: 10.2147/DDDT.S84264. eCollection 2016. Review. Erratum in: Drug Des Devel Ther. 2016;10:697. PubMed PMID: 26869769; PubMed Central PMCID: PMC4734733.
4: Iba K, Sonoda T, Takada J, Dohke T, Yamashita T. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment. J Bone Miner Metab. 2016 Jan 30. [Epub ahead of print] PubMed PMID: 26832388.
5: Mukaiyama K, Uchiyama S, Nakamura Y, Ikegami S, Taguchi A, Kamimura M, Kato H. Eldecalcitol, in Combination with Bisphosphonate, Is Effective for Treatment of Japanese Osteoporotic Patients. Tohoku J Exp Med. 2015;237(4):339-43. doi: 10.1620/tjem.237.339. PubMed PMID: 26639092.
6: Serizawa K, Yogo K, Tashiro Y, Takeda S, Kawasaki R, Aizawa K, Endo K. Eldecalcitol prevents endothelial dysfunction in postmenopausal osteoporosis model rats. J Endocrinol. 2016 Feb;228(2):75-84. doi: 10.1530/JOE-15-0332. Epub 2015 Nov 4. PubMed PMID: 26537128.
7: Shintani T, Rosli SN, Takatsu F, Choon YF, Hayashido Y, Toratani S, Usui E, Okamoto T. Eldecalcitol (ED-71), an analog of 1α,25-dihydroxyvitamin D3 as a potential anti-cancer agent for oral squamous cell carcinomas. J Steroid Biochem Mol Biol. 2015 Oct 9. pii: S0960-0760(15)30102-3. doi: 10.1016/j.jsbmb.2015.09.043. [Epub ahead of print] Review. PubMed PMID: 26444325.
8: Saito M, Marumo K. [Bone Cell Biology Assessed by Microscopic Approach. The effects of active vitamin D3 such as alfacalcidol and eldecalcitol on bone quality]. Clin Calcium. 2015 Oct;25(10):1541-54. doi: CliCa151015411554. Japanese. PubMed PMID: 26412735.
9: Ebina K, Noguchi T, Hirao M, Kaneshiro S, Tsukamoto Y, Yoshikawa H. Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis. J Bone Miner Metab. 2016 May;34(3):243-50. doi: 10.1007/s00774-015-0710-2. Epub 2015 Aug 25. Review. PubMed PMID: 26303222.
10: Sakai S, Takeda S, Sugimoto M, Shimizu M, Shimonaka Y, Yogo K, Hashimoto J, Bauss F, Endo K. Treatment with the combination of ibandronate plus eldecalcitol has a synergistic effect on inhibition of bone resorption without suppressing bone formation in ovariectomized rats. Bone. 2015 Dec;81:449-58. doi: 10.1016/j.bone.2015.08.004. Epub 2015 Aug 15. PubMed PMID: 26281770.
11: Saito K, Miyakoshi N, Matsunaga T, Hongo M, Kasukawa Y, Shimada Y. Eldecalcitol improves muscle strength and dynamic balance in postmenopausal women with osteoporosis: an open-label randomized controlled study. J Bone Miner Metab. 2015 Jul 25.
Name: Eldecalcitol
CAS NO.: 104121-92-8
Chemical Formula: C30H50O5
Exact Mass: 490.3658
Molecular Weight: 490.725
Elemental Analysis: C, 73.43; H, 10.27; O, 16.30
1. ED-71 intermediates 1, CAS No.:70550-73-1, NMR, HPLC 98%, LCMS, COA, 10G in stock.
CHEMICAL STRUCTURE:
2. ED-71 intermediates 2, CAS No.:144901-90-6, NMR, HPLC 98%, LCMS, COA, 10g in stock.
CHEMICAL STRUCTURE:
 |
3. ED-71 intermediates 3, CAS No.:239100-35-7, NMR, HPLC 98%, LCMS, COA, 8g in stock.
CHEMICAL STRUCTURE:
4. ED-71 intermediates 4, CAS No.:64190-52-9, NMR, HPLC 98%, LCMS, COA, 10g in stock.
CHEMICAL STRUCTURE:
5. ED-71 intermediates 5, CAS No.:79918-70-0, NMR, HPLC 98%, LCMS, COA, 5g in stock.
CHEMICAL STRUCTURE:
2017 China CPHI: E1M35
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
労働時間: Beijing Time 4:00AM~11:00PM
郵箱: info@eosmedchem.com ; eosmedchem@gmail.com
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp & Wechat: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
Skype: willgutian
QQ: 2393923585
REFERENCES
1: Takada J, Ikeda S, Kusanagi T, Mizuno S, Wada H, Iba K, Yoshizaki T, Yamashita T. Comparison of the effects of eldecalcitol with either raloxifene or bisphosphonate on serum tartrate resistant acid phosphatase-5b, a bone resorption marker, in postmenopausal osteoporosis. Clin Cases Miner Bone Metab. 2016 Jan-Apr;13(1):25-8. doi: 10.11138/ccmbm/2016.13.1.025. Epub 2016 May 11. PubMed PMID: 27252739; PubMed Central PMCID: PMC4869948.
2: Erratum: Treatment of osteoporosis with eldecalcitol, a new vitamin D analog: a comprehensive review and meta-analysis of randomized clinical trials [Corrigendum]. Drug Des Devel Ther. 2016 Feb 15;10:697. doi: 10.2147/DDDT.S105820. eCollection 2016. PubMed PMID: 26929600; PubMed Central PMCID: PMC4760662.
3: Xu Z, Fan C, Zhao X, Tao H. Treatment of osteoporosis with eldecalcitol, a new vitamin D analog: a comprehensive review and meta-analysis of randomized clinical trials. Drug Des Devel Ther. 2016 Jan 28;10:509-17. doi: 10.2147/DDDT.S84264. eCollection 2016. Review. Erratum in: Drug Des Devel Ther. 2016;10:697. PubMed PMID: 26869769; PubMed Central PMCID: PMC4734733.
4: Iba K, Sonoda T, Takada J, Dohke T, Yamashita T. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment. J Bone Miner Metab. 2016 Jan 30. [Epub ahead of print] PubMed PMID: 26832388.
5: Mukaiyama K, Uchiyama S, Nakamura Y, Ikegami S, Taguchi A, Kamimura M, Kato H. Eldecalcitol, in Combination with Bisphosphonate, Is Effective for Treatment of Japanese Osteoporotic Patients. Tohoku J Exp Med. 2015;237(4):339-43. doi: 10.1620/tjem.237.339. PubMed PMID: 26639092.
6: Serizawa K, Yogo K, Tashiro Y, Takeda S, Kawasaki R, Aizawa K, Endo K. Eldecalcitol prevents endothelial dysfunction in postmenopausal osteoporosis model rats. J Endocrinol. 2016 Feb;228(2):75-84. doi: 10.1530/JOE-15-0332. Epub 2015 Nov 4. PubMed PMID: 26537128.
7: Shintani T, Rosli SN, Takatsu F, Choon YF, Hayashido Y, Toratani S, Usui E, Okamoto T. Eldecalcitol (ED-71), an analog of 1α,25-dihydroxyvitamin D3 as a potential anti-cancer agent for oral squamous cell carcinomas. J Steroid Biochem Mol Biol. 2015 Oct 9. pii: S0960-0760(15)30102-3. doi: 10.1016/j.jsbmb.2015.09.043. [Epub ahead of print] Review. PubMed PMID: 26444325.
8: Saito M, Marumo K. [Bone Cell Biology Assessed by Microscopic Approach. The effects of active vitamin D3 such as alfacalcidol and eldecalcitol on bone quality]. Clin Calcium. 2015 Oct;25(10):1541-54. doi: CliCa151015411554. Japanese. PubMed PMID: 26412735.
9: Ebina K, Noguchi T, Hirao M, Kaneshiro S, Tsukamoto Y, Yoshikawa H. Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis. J Bone Miner Metab. 2016 May;34(3):243-50. doi: 10.1007/s00774-015-0710-2. Epub 2015 Aug 25. Review. PubMed PMID: 26303222.
10: Sakai S, Takeda S, Sugimoto M, Shimizu M, Shimonaka Y, Yogo K, Hashimoto J, Bauss F, Endo K. Treatment with the combination of ibandronate plus eldecalcitol has a synergistic effect on inhibition of bone resorption without suppressing bone formation in ovariectomized rats. Bone. 2015 Dec;81:449-58. doi: 10.1016/j.bone.2015.08.004. Epub 2015 Aug 15. PubMed PMID: 26281770.
11: Saito K, Miyakoshi N, Matsunaga T, Hongo M, Kasukawa Y, Shimada Y. Eldecalcitol improves muscle strength and dynamic balance in postmenopausal women with osteoporosis: an open-label randomized controlled study. J Bone Miner Metab. 2015 Jul 25.
